title: Osteoporosis and multiple fractures in an antiretroviral-naive, HIV-positive child.
abstract: As a result of the increased incidence of osteopenia and osteoporosis in HIV-infected patients, numerous publications have suggested that there may be a link between bone metabolism alterations and HIV infection. The early bone loss seen in these patients was initially attributed to the use of highly active antiretroviral treatment (HAART) that included protease inhibitors. Recent studies, however, have suggested that it may be a direct consequence of the viral infection on bone metabolism, persistent activation of pro-inflammatory cytokines (TNFa), or altered vitamin D metabolism secondary to the virus, combined with subsequent factors (e.g., antiretroviral treatment) that aggravate the bone demineralization. We present an antiretroviral-naive 6-year-old girl with vertically transmitted HIV infection who presented with severe osteoporosis and multiple pathological fractures of the vertebrae, ribs, and upper and lower limbs. The child was treated with HAART, appropriate nutritional support for her age, physiotherapy and rehabilitation, calcium and vitamin D supplements, and alendronate therapy. After 6 weeks of treatment, the intense pain and muscle atrophy had disappeared and she was able to walk unassisted. At 6 months, bone mass had increased by 72%. The interest of this case lies in the presence of severe osteoporosis and multiple pathological fractures in an HIVinfected naive child. To date, this condition has only been described in patients treated with antiretrovirals. Moreover, this is the first reported HIV-positive pediatric patient treated with bisphosphonates, which proved to be highly successful.
authors.affiliation: Pediatric Infectious Disease Unit, University Hospital Vall d'Hebron, Barcelona, Spain. psoler@vhebron.net
authors.forename: P
authors.initials: P
authors.lastname: Soler Palacin
authors.forename: A
authors.initials: A
authors.lastname: Torrent
authors.forename: R
authors.initials: R
authors.lastname: Rossich
authors.forename: F A
authors.initials: FA
authors.lastname: Moraga
authors.forename: D
authors.initials: D
authors.lastname: Yeste
authors.forename: J C
authors.initials: JC
authors.lastname: Carreño
authors.forename: G
authors.initials: G
authors.lastname: Encabo
authors.forename: C
authors.initials: C
authors.lastname: Figueras
mesh_terms: D019380:Anti-HIV Agents / Q000008:administration & dosage; D023241:Antiretroviral Therapy, Highly Active; D002648:Child; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D050723:Fractures, Bone / Q000000981:diagnostic imaging / Q000209:etiology* / Q000517:prevention & control / Q000821:virology; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006679:HIV Seropositivity / Q000150:complications*; D006801:Humans; D010024:Osteoporosis / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000209:etiology* / Q000821:virology; D011859:Radiography; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents; D004164:Diphosphonates